Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A

References

• Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost. 2014 Jul;40(5):571–576.
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of hemophilia. Srivastava A1, Brewer AK, Mauser-Bunschoten EP et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Haemophilia. 2013 Jan;19(1):e1–47.
   Google Scholar
• Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 2013;27:179–184.
   PubMed Web of Science ®Google Scholar
• Berntorp E. Prophylactic therapy for haemophilia: early experience. Haemophilia. 2003 May;9(1):5–9.
   PubMedGoogle Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038–2045.
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14(5):931–938.
   PubMed Web of Science ®Google Scholar
• Duncan N, Shapiro A, Ye X, et al. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia. 2012;18(5):760–765.
   PubMed Web of Science ®Google Scholar
• Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012 Mar 29;119(13):3024–3030.
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013 Mar 14;121(11):2108–2116.
   PubMed Web of Science ®Google Scholar
• Ragni MV. New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins. Drugs. 2015;75(14):1587–1600.
   PubMed Web of Science ®Google Scholar
• Kepa S, Horvath B, Reitter-Pfoertner S, et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015;21(3):343–350.
   PubMed Web of Science ®Google Scholar
• Vlot AJ, Koppelman SJ, Meijers JCM, et al. Kinetics of factor VIII-von Willebrand factor association. Blood. 1996;87(5):1809–1816.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007 Jan 15;109(2):610–612.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Di Minno G, Di Capua M, et al. Cost of care of haemophilia with inhibitors. Haemophilia. 2010;16:e190–e201.
   PubMedGoogle Scholar
• DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13:1–22.
   PubMed Web of Science ®Google Scholar
• Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2010;16:66–70.
   PubMed Web of Science ®Google Scholar
• Saenko EL, Ananyeva NM. Receptor-mediated clearance of factor VIII: implications for pharmacokinetic studies in individuals with haemophilia. Haemophilia. 2006;12:15–22.
   PubMed Web of Science ®Google Scholar
• Kaveri SV, Dasgupta S, Andre S, et al. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia. 2007;13(Suppl. 5):61–64.
   PubMedGoogle Scholar
• Lacroix-Desmazes S, Navarrete AM, Andre S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood. 2008;112:240–9.104.
   PubMed Web of Science ®Google Scholar
• Pipe SW, Montgomery RR, Pratt KP, et al. Life in the shadow of a dominant partner: the FVIII VWF association and its clinical implications for hemophilia A. Blood. 2016 Oct 20;128(16):2007–2016.
   PubMed Web of Science ®Google Scholar
• Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006;12(suppl 6):102–106.
   PubMed Web of Science ®Google Scholar
• Behrmann M, Pasi J, Saint-Remy JM, et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost. 2002;88(2):221–229.
   PubMed Web of Science ®Google Scholar
• Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol. 2006;13(5):316–322.
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8(6):1256–1265.
   PubMed Web of Science ®Google Scholar
• Goudemand J, Rothschild C, Demiguel V, et al. FVIII-LFB and recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107(1):46–51.
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost. 2013 Oct;39(7):752–766.
   PubMed Web of Science ®Google Scholar
• Gouw S, van der Bom J, Auerswald G, et al. Recombinant versus plasma derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4693–4697.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–2064.
   PubMed Web of Science ®Google Scholar
• Fischer K, Blatny J. Do the SIPPET study results apply to the patients I treat? Haemophilia. 2017 May;23(3):348–349.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–4055.
   PubMed Web of Science ®Google Scholar
• Schmidbauer S, Witzel R, Robbel L, et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2015;136:388–395.
   PubMed Web of Science ®Google Scholar
• Sawamoto Y, Prescott R, Zhong D, et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost. 1998;79:62–68.
   PubMed Web of Science ®Google Scholar
• Zollner S, Raquet E, Claar P, et al. Non clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134:125–131.
   PubMed Web of Science ®Google Scholar
• Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013 Aug;132(2):280–287.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Kuliczkowski K, Karim FA. AFFINITY investigators efficacy and safety of rVIIISingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 Aug 4;128(5):630–637.
   PubMed Web of Science ®Google Scholar
• Stasyshyn O, Khayat CD, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost. 2017 Feb;15(4):636–644.
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11:670–678.
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain–deleted recombinant FVIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496.
   PubMed Web of Science ®Google Scholar
• Carlsson M, Berntorp E, Bjorkman S, et al. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol. 1993;51:247–252.
   PubMed Web of Science ®Google Scholar
• Steele MR, Nagel K, Chan AK, et al. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A. Haemophilia. 2014;20:e100–1.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6:1319–1326.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–832.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Roberts J, Tortorici M, et al. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J Thromb Haemost. 2017 Feb 15;15(6):1106–1114.
   PubMed Web of Science ®Google Scholar
• Cannavò A, Valsecchi C, Garagiola I, et al. Non-neutralizing antibodies against factor VIII and risk of inhibitor development in severe haemophilia A. Blood. 2017 Mar 9;129(10):1245–1250.
   PubMedGoogle Scholar
• St Ledger K, Fuessner A, Kalina U, et al. Characteristics of rVIII SingleChain in the one-stage and the chromogenic substrate assay: results of an international field study. Haemophilia. 2016;22:59.
   Web of Science ®Google Scholar
• Morfini M, Cinotti S, Bellatreccia A, et al. A multicentre pharmacokinetic study of the B domain deleted recombinant factor VIII concentrate suing different assays and standards. J Thromb Haemost. 2003;1:2283–2289.
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Jankowski MA, Weston SB, et al. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDD Factor VIII: C activity in hemophilic plasma using the one-stage clotting assay. J Thromb Haemost. 2004;2:623–628.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691–697.
   PubMed Web of Science ®Google Scholar
• Pouplard C, Ternisien C, Desconclois C, et al. Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF-treated patients. Haemophilia. 2016 Jan 29;22:101–103.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Negrier C, Kohla G, et al. The first recombinant FVIII produced in human cells – an update on its clinical development programme. Haemophilia. 2014;20(suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay CR, et al. RAHFPFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5):428–437.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. A-LONG investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16;123(3):317–325.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078–1085.
   PubMed Web of Science ®Google Scholar
• Kitchen S, Kershaw G, Tiefenbacher S. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues. Haemophilia. 2016 Jul;22(Suppl 5):72–77. Review.
   PubMed Web of Science ®Google Scholar
• Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016 Jul;22(4):487–498.
   PubMed Web of Science ®Google Scholar
• Maraskovsky AE, Verhagen A, Huynh H, et al. Profiling and comparing the immunogenicity of a novel single-chain FVIII molecule (rVIII-SingleChain) for the treatment of hemophilia. Blood. 2016;128:4960 Absract.
   Web of Science ®Google Scholar
• Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica. 2003;88(6).
   Google Scholar
• Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis. 2005;16(Suppl 1):S27–31.
   PubMed Web of Science ®Google Scholar
• Kreuz W, Escuriola EC, Vdovin V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016;22:87–95.
   PubMed Web of Science ®Google Scholar
• Robertson JD, Higgins P, Price J, et al. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study. Thromb Res. 2014;134:1046–1051.
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:436–463.
   PubMed Web of Science ®Google Scholar